Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
7.62
+0.13 (1.74%)
Nov 21, 2024, 4:00 PM EST - Market closed

Company Description

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States.

The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.

Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics.

Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Kezar Life Sciences, Inc.
Kezar Life Sciences logo
Country United States
Founded 2015
IPO Date Jun 21, 2018
Industry Biotechnology
Sector Healthcare
Employees 58
CEO Christopher Kirk

Contact Details

Address:
4000 Shoreline Court, Suite 300
South San Francisco, California 94080
United States
Phone 650 822 5600
Website kezarlifesciences.com

Stock Details

Ticker Symbol KZR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001645666
CUSIP Number 49372L100
ISIN Number US49372L1008
Employer ID 47-3366145
SIC Code 2834

Key Executives

Name Position
Dr. Christopher J. Kirk Ph.D. Co-Founder, Chief Executive Officer and Director
John Franklin Fowler Co-Founder and Director
Dr. Jack Taunton Ph.D. Co-Founder
Gitanjali Jain Senior Vice President of Investor Relations and External Affairs
Mark Schiller Chief Legal Officer
Joe Tedrick Vice President of Human Resources
Dr. Neel K. Anand Ph.D. Senior Vice President of Research and Drug Discovery
Zung To Senior Vice President of Clinical Development
Pattie Chiang Senior Vice President and Corporate Controller

Latest SEC Filings

Date Type Title
Nov 14, 2024 8-K Current Report
Nov 14, 2024 SCHEDULE 13G/A Filing
Nov 12, 2024 10-Q Quarterly Report
Nov 12, 2024 8-K Current Report
Oct 29, 2024 8-A12B/A Filing
Oct 28, 2024 8-K Current Report
Oct 17, 2024 8-A12B Registration of securities
Oct 17, 2024 8-K Current Report
Oct 10, 2024 8-K Current Report
Oct 8, 2024 SC 13D General statement of acquisition of beneficial ownership